دورية أكاديمية
The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol.
| العنوان: | The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well-controlled plasma LDL cholesterol. |
|---|---|
| المؤلفون: | Bouter KEC; Department of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Centers, the Netherlands., van Bommel EJM; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, the Netherlands., Jansen H; Department of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Centers, the Netherlands., van Harskamp D; Department of Clinical Chemistry, Laboratory of Endocrinology, Amsterdam University Medical Centers, the Netherlands., Schierbeek H; Department of Clinical Chemistry, Laboratory of Endocrinology, Amsterdam University Medical Centers, the Netherlands., Ackermans MT; Department of Clinical Chemistry, Laboratory of Endocrinology, Amsterdam University Medical Centers, the Netherlands., Serlie MJ; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, the Netherlands., Schimmel AWM; Department of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Centers, the Netherlands., Nieuwdorp M; Department of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Centers, the Netherlands., Dallinga-Thie GM; Department of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Centers, the Netherlands., van Raalte DH; Department of Vascular Medicine and Experimental Vascular Medicine, Amsterdam University Medical Centers, the Netherlands.; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, the Netherlands. |
| المصدر: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Jun; Vol. 22 (6), pp. 988-996. Date of Electronic Publication: 2020 Feb 27. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Oxford : Wiley-Blackwell, c1999- |
| مواضيع طبية MeSH: | Apolipoproteins B* , Benzhydryl Compounds*/therapeutic use , Diabetes Mellitus, Type 2*/drug therapy , Glucosides*/therapeutic use, Adult ; Apolipoprotein B-100 ; Cholesterol, HDL ; Cholesterol, LDL ; Glucose ; Humans ; Male ; Plasma ; Triglycerides |
| مستخلص: | Aim: To dissect the effects of the sodium-glucose linked transporter 2 inhibitor dapagliflozin on lipid metabolism and assess whether these effects could potentially offset cardiovascular benefit with this drug-class. Materials and Methods: We assessed the effect of dapagliflozin on lipid metabolism in 11 adults with uncomplicated type 2 diabetes. After 4 weeks of statin wash-out and 4 weeks of rosuvastatin 10 mg treatment, participants were treated with dapagliflozin 10 mg once-daily for 5 weeks. Before and after dapagliflozin, plasma lipids were measured and very low-density lipoprotein (VLDL)-1 and VLDL-2 apolipoprotein (Apo)B fluxes were assessed using (5.5.5- 2 H Results: Rosuvastatin decreased all plasma lipids significantly: total cholesterol from 4.5 (3.2-6.2) to 3.1 (2.5-3.8) mmol/L, LDL cholesterol from 2.6 (1.7-3.4) to 1.5 (1.1-2.2) mmol/L, HDL cholesterol from 1.34 (0.80-2.02) to 1.19 (0.74-1.89) mmol/L and triglycerides from 0.92 (0.31-3.91) to 0.79 (0.32-2.10) mmol/L. The addition of dapaglifozin to rosuvastatin did not raise either LDL cholesterol or total cholesterol, and only increased HDL cholesterol by 0.08 (-0.03-0.13) mmol/L (P = 0.03). In line with this, dapagliflozin did not affect VLDL-1 or VLDL-2 ApoB fluxes. Fasting endogenous glucose production tended to increase by 0.9 (-3.4-3.1) μmol kg -1 min -1 (P = 0.06), but no effect on hepatic and peripheral insulin sensitivity or on peripheral lipolysis was observed. Conclusions: Dapagliflozin has no effect on plasma LDL-cholesterol levels or VLDL-apoB fluxes in the context of optimal lipid-lowering treatment, which will thus not limit cardiovascular benefit when lipids are adequately controlled. (© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.) |
| References: | N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602) J Clin Invest. 2014 Feb;124(2):499-508. (PMID: 24463454) BMJ. 1998 Mar 14;316(7134):823-8. (PMID: 9549452) Cell Metab. 2017 Oct 3;26(4):611-619.e6. (PMID: 28978426) Diabetologia. 2018 Mar;61(3):722-726. (PMID: 29197997) Diabetologia. 2011 Aug;54(8):2103-12. (PMID: 21562755) N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427) J Clin Endocrinol Metab. 2001 May;86(5):2220-6. (PMID: 11344230) Clin J Am Soc Nephrol. 2017 Apr 3;12(4):700-710. (PMID: 28254770) Lancet. 2019 Jan 5;393(10166):31-39. (PMID: 30424892) Diabetes Obes Metab. 2020 Jun;22(6):988-996. (PMID: 32026592) Am J Physiol. 1996 Jun;270(6 Pt 1):E1022-36. (PMID: 8764188) Diab Vasc Dis Res. 2015 Mar;12(2):90-100. (PMID: 25589482) Adv Ther. 2017 Feb;34(2):436-451. (PMID: 27981497) N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608) N Engl J Med. 2013 Oct 3;369(14):1317-26. (PMID: 23992601) N Engl J Med. 2008 Jun 12;358(24):2545-59. (PMID: 18539917) N Engl J Med. 2007 Jun 14;356(24):2457-71. (PMID: 17517853) N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978) Lancet. 1998 Sep 12;352(9131):854-65. (PMID: 9742977) J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. (PMID: 30999996) Diabetes. 2016 Jul;65(7):2032-8. (PMID: 27207551) J Clin Invest. 2014 Feb;124(2):509-14. (PMID: 24463448) Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1287-1302. (PMID: 30463454) Am J Clin Nutr. 2008 Oct;88(4):997-1003. (PMID: 18842786) Diabetologia. 2017 Mar;60(3):568-573. (PMID: 27752710) J Appl Physiol Respir Environ Exerc Physiol. 1983 Aug;55(2):628-34. (PMID: 6618956) Diabetes Care. 2018 Feb;41(2):356-363. (PMID: 29203583) Lancet. 2009 May 23;373(9677):1765-72. (PMID: 19465231) Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):2207-2216. (PMID: 30354257) Ann Intern Med. 2013 Aug 20;159(4):262-74. (PMID: 24026259) Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123. (PMID: 30559236) |
| معلومات مُعتمدة: | International The study was funded by an unrestricted grant from AstraZeneca. |
| فهرسة مساهمة: | Keywords: LDL cholesterol; apolipoprotein B; dapagliflozin; glucose; insulin sensitivity; lipolysis; sodium-glucose co-transporter-2 inhibitor; type 2 diabetes |
| المشرفين على المادة: | 0 (Apolipoprotein B-100) 0 (Apolipoproteins B) 0 (Benzhydryl Compounds) 0 (Cholesterol, HDL) 0 (Cholesterol, LDL) 0 (Glucosides) 0 (Triglycerides) 1ULL0QJ8UC (dapagliflozin) IY9XDZ35W2 (Glucose) |
| تواريخ الأحداث: | Date Created: 20200207 Date Completed: 20210531 Latest Revision: 20210531 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7318266 |
| DOI: | 10.1111/dom.13990 |
| PMID: | 32026592 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.13990 |